Arietis is a Boston-based biotechnology company focused on the discovery and development of novel antimicrobial agents.

Copyright © 2016 Arietis Corporation - All Rights Reserved

Arietis is located at the Bio Square Discovery and Innovation Center on Boston University's Medical Campus.  Arietis was founded on technologies for discovering antimicrobials developed by Professor Kim Lewis at Northeastern University.  Dr. Ken Coleman serves as Chief Scientific Officer and Dr. Michael LaFleur oversees daily laboratory operations. Following is a brief description of their backgrounds.


Kim Lewis, Ph.D.

Founder & Chairman of the Board

Dr. Lewis is a Professor of Biology and Director of the Antimicrobial Discovery Center at Northeastern University. He is an expert in microbial drug resistance and drug discovery. He received his Ph.D. in Biochemistry from Moscow University and prior to coming to NEU in 2001 has been on the Faculty of MIT, University of Maryland and Tufts University. Dr. Lewis is the author of over 100 publications, several patents and inventions licensed to the Industry.


Ken Coleman, Ph.D.

Chief Scientific Officer

Dr. Coleman has more than 35 years of experience in antimicrobial drug discovery and development in both large pharma and small biotech companies. He has a number of successful drugs in his portfolio, including developing of clavulanic acid and gemifloxacin.


Michael LaFleur, Ph.D.

Chief Operating Officer

Dr. LaFleur is a co-inventor on key Arietis technology and has led operations since 2008. Michael received his Ph.D. from Northeastern University, and has worked closely with Dr. Lewis to understand recalcitrant infections, and develop therapeutic approaches to make these infections treatable.